JP7618950B2 - 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物 - Google Patents

免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物 Download PDF

Info

Publication number
JP7618950B2
JP7618950B2 JP2021516357A JP2021516357A JP7618950B2 JP 7618950 B2 JP7618950 B2 JP 7618950B2 JP 2021516357 A JP2021516357 A JP 2021516357A JP 2021516357 A JP2021516357 A JP 2021516357A JP 7618950 B2 JP7618950 B2 JP 7618950B2
Authority
JP
Japan
Prior art keywords
antibody
tumor
cells
toxin
analogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021516357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511337A5 (cg-RX-API-DMAC7.html
JP2022511337A (ja
Inventor
ローレンス,トビー
クラー モーストルップ,ソーレン
エゼロット,アンダース
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aix-Marseille Université
Centre National de la Recherche Scientifique
Original Assignee
Aix-Marseille Université
Centre National de la Recherche Scientifique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aix-Marseille Université, Centre National de la Recherche Scientifique filed Critical Aix-Marseille Université
Publication of JP2022511337A publication Critical patent/JP2022511337A/ja
Publication of JP2022511337A5 publication Critical patent/JP2022511337A5/ja
Priority to JP2024223694A priority Critical patent/JP2025038162A/ja
Application granted granted Critical
Publication of JP7618950B2 publication Critical patent/JP7618950B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021516357A 2018-09-19 2019-09-18 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物 Active JP7618950B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024223694A JP2025038162A (ja) 2018-09-19 2024-12-19 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306219 2018-09-19
EP18306219.9 2018-09-19
PCT/EP2019/075080 WO2020058372A1 (en) 2018-09-19 2019-09-18 Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024223694A Division JP2025038162A (ja) 2018-09-19 2024-12-19 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物

Publications (3)

Publication Number Publication Date
JP2022511337A JP2022511337A (ja) 2022-01-31
JP2022511337A5 JP2022511337A5 (cg-RX-API-DMAC7.html) 2022-09-07
JP7618950B2 true JP7618950B2 (ja) 2025-01-22

Family

ID=63787877

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021516357A Active JP7618950B2 (ja) 2018-09-19 2019-09-18 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物
JP2024223694A Pending JP2025038162A (ja) 2018-09-19 2024-12-19 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024223694A Pending JP2025038162A (ja) 2018-09-19 2024-12-19 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物

Country Status (5)

Country Link
US (1) US20220073638A1 (cg-RX-API-DMAC7.html)
EP (1) EP3853251A1 (cg-RX-API-DMAC7.html)
JP (2) JP7618950B2 (cg-RX-API-DMAC7.html)
CN (1) CN113396160A (cg-RX-API-DMAC7.html)
WO (1) WO2020058372A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025038162A (ja) * 2018-09-19 2025-03-18 インサーム (インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル) 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11634501B2 (en) 2019-07-19 2023-04-25 Oncoresponse, Inc. Immunomodulatory antibodies and methods of use thereof
US20220363776A1 (en) * 2019-10-04 2022-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
CA3233490A1 (en) * 2021-09-28 2023-04-06 The Trustees Of The University Of Pennsylvania Compositions and methods for t cell targeted delivery of therapeutic agents
CN114694745A (zh) * 2022-03-24 2022-07-01 至本医疗科技(上海)有限公司 预测免疫疗效的方法、装置、计算机设备和存储介质
WO2024015560A1 (en) * 2022-07-15 2024-01-18 Whitehead Institute For Biomedical Research Combination of macrophage-directed immunotherapy and cytokines for treatment of cancer
JP2026519901A (ja) 2023-01-27 2026-06-19 ヴィーアイビー ヴィーゼットヴィー Cd163結合複合体
EP4563596A1 (en) * 2023-11-30 2025-06-04 OncoSpear ApS Anti-cd163 antibodies with improved adcc capabilities
AU2024391672A1 (en) 2023-11-30 2026-05-21 Oncospear Aps Anti-cd163 antibodies with improved adcc capabilities
WO2025207936A1 (en) * 2024-03-28 2025-10-02 Mirror Biologics, Inc. Treatment for colorectal cancer using immune checkpoint inhibitors
CN120695211A (zh) * 2025-06-25 2025-09-26 广东医科大学附属医院 mRNA组合物及其在制备肝纤维化治疗药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533912A (ja) 2014-10-29 2017-11-16 ファイヴ プライム セラピューティクス インク がんのための併用療法
WO2018156725A1 (en) 2017-02-24 2018-08-30 Thomas Jefferson University Methods and compositions for inhibiting tumor growth and enhancing immune responses to tumors
WO2018158658A1 (en) 2017-03-03 2018-09-07 Rinat Neuroscience Corp. Anti-gitr antibodies and methods of use thereof

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
EP0970128A1 (en) 1997-03-21 2000-01-12 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
GB0229734D0 (en) 2002-12-23 2003-01-29 Qinetiq Ltd Grading oestrogen and progesterone receptors expression
US7257268B2 (en) 2003-02-28 2007-08-14 Aperio Technologies, Inc. Systems and methods for image pattern recognition
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7837980B2 (en) 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
JP2008519863A (ja) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド N末端にアミノ安息香酸単位を有するオーリスタチン
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP1898529A1 (en) 2005-06-28 2008-03-12 Pioneer Corporation Broadcast receiving apparatus, interference detecting apparatus and interference detecting method
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
US8023714B2 (en) 2007-06-06 2011-09-20 Aperio Technologies, Inc. System and method for assessing image interpretability in anatomic pathology
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
CN102165489B (zh) 2008-09-16 2015-11-25 赫斯托克斯公司 生物标志物表达的可再现量化
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
US8345509B2 (en) 2009-04-16 2013-01-01 Chevron U.S.A., Inc. System and method to create three-dimensional images of non-linear acoustic properties in a region remote from a borehole
GB0917044D0 (en) * 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
US20110111435A1 (en) 2009-11-06 2011-05-12 SlidePath Limited Detecting Cell Surface Markers
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
CN103079644B (zh) 2010-06-11 2017-02-15 协和发酵麒麟株式会社 抗tim‑3抗体
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
HUE039339T2 (hu) 2013-03-15 2018-12-28 Bristol Myers Squibb Co Indolamin-2,3-dioxigenáz (IDO) inhibitorai
RS57508B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,2,4-derivati oksadiazola kao imunomodulatori
TR201811077T4 (tr) 2013-09-06 2018-08-27 Aurigene Discovery Tech Ltd İmmünomodülatörler olarak 1,3,4-oksadiazol ve 1,3,4-tiyadiyazol türevleri.
CR20180243A (es) 2015-10-02 2018-07-31 Genentech Inc Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
US10617672B2 (en) * 2015-10-15 2020-04-14 Lipomedix Pharmaceuticals Ltd. Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin C
CN108495651A (zh) * 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
ITUB20160191A1 (it) * 2016-01-21 2017-07-21 Invectors S R L Kit per la preparazione di doxorubicina liposomiale funzionalizzata con peptidi per il target selettivo di recettori sovra espressi da cellule tumorali
CA3028589A1 (en) * 2016-06-21 2017-12-28 Therapure Biopharma Inc. Hemoglobin-targeted drug delivery for the treatment of cancer
EP3491387A1 (en) * 2016-07-28 2019-06-05 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods of treatement of cancer disease by targetting tumor associated macrophage
EP3504239B1 (en) * 2016-08-25 2024-05-29 F. Hoffmann-La Roche AG Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
IL317919A (en) * 2016-12-05 2025-02-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
WO2020058372A1 (en) * 2018-09-19 2020-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533912A (ja) 2014-10-29 2017-11-16 ファイヴ プライム セラピューティクス インク がんのための併用療法
WO2018156725A1 (en) 2017-02-24 2018-08-30 Thomas Jefferson University Methods and compositions for inhibiting tumor growth and enhancing immune responses to tumors
WO2018158658A1 (en) 2017-03-03 2018-09-07 Rinat Neuroscience Corp. Anti-gitr antibodies and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Jonas Heilskov Graversen, Soren Kragh Moestrup,Drug Trafficking into Macrophages via the Endocytotic Receptor CD163,Membranes, Vol. 5,228-252,https://www.mdpi.com/2077-0375/5/2/228
Journal of Controlled Release,2012年,Vol.160,pp.72-80

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025038162A (ja) * 2018-09-19 2025-03-18 インサーム (インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル) 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物

Also Published As

Publication number Publication date
EP3853251A1 (en) 2021-07-28
JP2025038162A (ja) 2025-03-18
WO2020058372A1 (en) 2020-03-26
CN113396160A (zh) 2021-09-14
JP2022511337A (ja) 2022-01-31
US20220073638A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
JP2025038162A (ja) 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物
JP7153626B2 (ja) 抗ヒト4-1bb抗体およびその使用
JP7129449B2 (ja) ヒト化ccケモカイン受容体4(ccr4)抗体およびその使用法
KR102291971B1 (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
KR20180081606A (ko) 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제
CA2851762A1 (en) Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
US20090299038A1 (en) Anti-hdlk-1 antibody having an antitumor activity in vivo
AU2007318483A1 (en) Anti-human Dlk-1 antibody showing anti-tumor activity in vivo
US20240175873A1 (en) Methods for the diagnosis and treatment of t cell-lymphomas
CN113544151A (zh) 抗il-27抗体及其用途
CN108474793A (zh) 预后方法
WO2019089753A2 (en) Cd137 antibodies and pd-1 antagonists and uses thereof
TW202116807A (zh) 用於治療特定患者之癌症的抗體組合
TW202340243A (zh) 抗cd39抗體及其用途
JP6159010B2 (ja) テトラスパニン8に対するハイブリドーマクローンおよびモノクローナル抗体
JP6159011B2 (ja) Cd9に対するハイブリドーマクローンおよびモノクローナル抗体
KR102487356B1 (ko) 종양 관련 대식세포를 표적화하는 항체 및 이의 용도
WO2019199896A1 (en) Agonist antibodies against human cd137 in cancer that express mhc i
WO2024003310A1 (en) Methods for the diagnosis and treatment of acute lymphoblastic leukemia
JP2020507576A (ja) Mapk経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
JP2023525053A (ja) 皮膚t細胞リンパ腫及びtfh由来リンパ腫を処置する新しい方法
CN117177771A (zh) 一种诊断和治疗t细胞淋巴瘤的方法
EP4508432A1 (en) Methods for the diagnosis and treatment of t-cell malignancies
WO2023198874A1 (en) Methods for the diagnosis and treatment of t cell-lymphomas
WO2024023283A1 (en) Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220830

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240802

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241219

R150 Certificate of patent or registration of utility model

Ref document number: 7618950

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150